For the first time since 2008, the number of biotherapeutic developers manufacturing 100% in-house has dropped in each production system surveyed. According to data released in BioPlan Associates’ 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1 for the first time since we began measuring outsourcing, more than half of respondents using mammalian cell culture or microbial fermentation systems report that they are now outsourcing at least some of thei...